Your session is about to expire
← Back to Search
Virus Therapy
Bacteriophage Therapy for Cystic Fibrosis
Phase 1 & 2
Waitlist Available
Research Sponsored by BiomX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 18 years
Cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection receiving standard of care CF medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial is testing if a new drug is safe and if it can help reduce infection in people with CF.
Who is the study for?
Adults over 18 with cystic fibrosis and chronic lung infection caused by Pseudomonas aeruginosa can join. They must be clinically stable, able to produce sputum samples, and have a certain level of lung function (FEV1 ≥ 40%). Excluded are those with severe immune issues, prior bacteriophage therapy within six months, specific ongoing treatments for other conditions, or recent changes in CF modulator therapy.Check my eligibility
What is being tested?
The trial is testing BX004-A, a nebulized bacteriophage therapy against a placebo. The main goal is to check if it's safe and tolerable for patients. Researchers will also explore whether this treatment reduces the amount of Pseudomonas bacteria in the lungs.See study design
What are the potential side effects?
While not specified here, common side effects from similar therapies may include respiratory symptoms like coughing or wheezing due to inhalation of the substance; allergic reactions; fatigue; and gastrointestinal discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I have cystic fibrosis with a chronic lung infection due to Pseudomonas aeruginosa and am on standard CF treatments.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and tolerability
Other outcome measures
PsA burden in sputum at various timepoints
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BX004-AExperimental Treatment1 Intervention
Participants will be randomized to receive standard dose of nebulized bacteriophage
Group II: PlaceboPlacebo Group1 Intervention
Participants will be randomized to receive nebulized placebo
Find a Location
Who is running the clinical trial?
BiomX, Inc.Lead Sponsor
2 Previous Clinical Trials
66 Total Patients Enrolled
Xilla Ussery, MDStudy DirectorBiomX, Inc.
Urania Rappo, MDStudy DirectorBiomX, Inc.
5 Previous Clinical Trials
749 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had severe low white blood cell counts.You are allergic to bacteriophages or other ingredients in the medicine.I have had a lung transplant.My lung condition is currently stable.I am currently being treated for a lung fungus allergy.I have not had bacteriophage therapy in the last 6 months.You have a weakened immune system.I am 18 years old or older.I am currently being treated for a non-tuberculous mycobacteria infection.I have had a solid organ transplant.You have been diagnosed with a Burkholderia species infection in your respiratory tract within the last year.I started or changed my cystic fibrosis treatment less than 3 months ago.I have cystic fibrosis with a chronic lung infection due to Pseudomonas aeruginosa and am on standard CF treatments.Your lung function (FEV1) is at least 40% of what is expected for someone your age and size.
Research Study Groups:
This trial has the following groups:- Group 1: BX004-A
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this trial accessible to patients in urban areas?
"Central Florida Pulmonary Group in Orlando, Florida, Boston Children's Hospital in Boston, Massachusetts, and Joe DiMaggio Children's Hospital in Hollywood, New york are all active participants in this clinical trial. Additionally, there are 7 other sites across the nation taking part."
Answered by AI
How many total individuals are taking part in this research?
"The correct, this particular study is recruiting patients according to the information available on clinicaltrials.gov. This specific trial was originally posted on 6/21/2022 and updated on 6/28/2022. They are looking for 32 individuals across 7 sites."
Answered by AI
Are there any available vacancies for test subjects in this experiment?
"That is correct. The information available on clinicaltrials.gov affirms that this particular trial is open and recruiting patients as of right now. This study was first made public on 6/21/2022 and the most recent update was on 6/28/2022. In total, 32 individuals are needed to complete this research project at 7 different locations."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger